Implications of all the available evidence
ACUTE RESPIRATORY INFECTIONS
Ritonavir-boosted nirmatrelvir has superior in-vivo antiviral activity in patients with early COVID-19 compared with molnupiravir. Candidate antivirals and antiviral combinations for COVID-19 should be assessed and compared using this method, which might also be applicable to other acute respiratory infections.